Symbols

Taysha Gene Therapies Stock Soars 7.91% on Clinical Trial Success!

Wednesday, Jun 4, 2025 6:36 am ET1min read

Taysha Gene Therapies, Inc. rose 7.91% in premarket trading. The company announced details for an oral presentation at a symposium, including clinical cohort data from high and low dose TSHA-102 trials, caregiver research supporting FDA alignment on primary endpoint, and preclinical data on broad biodistribution of AAV9 gene therapy vectors. These developments indicate progress in the company's lead clinical program for treating Rett syndrome, contributing to the stock's positive movement.

StockSavvy

Insightful stock picks for the savvy investor.

Latest Articles

Stay ahead of the market.

Get curated U.S. market news, insights and key dates delivered to your inbox.

Comments

﻿

Add a public comment...

No comments yet

AInvest
PRO

Editorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process. While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context. Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue